Home The Word Brain	My Amedeo FAQ Privacy About
	C49 + CC Journal Club For more information, please refer to our special emails from April 13 and May 19.

Liver Diseases

Free Subscription 26.05.2025 1 Am J Gastroenterol 1 Biochem Biophys Res Commun 4 BMC Cancer 5 BMC Gastroenterol 1 Br J Surg 2 Dig Dis Sci 3 Endoscopy 1 Eur Radiol 2 Gastroenterology 13 Hepatology 1 J Gastroenterol 2 J Gastroenterol Hepatol 4 J Hepatol 1 Oncogene 5 PLoS One 1 Proc Natl Acad Sci U S A 1 Semin Liver Dis 1 Transplantation

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Gastroenterol

1. DESAI AP, Scherer AN, Serper M
   The Role of Patient-Reported Outcomes in Cirrhosis.
   Am J Gastroenterol. 2025 May 20. doi: 10.14309/ajg.0000000000003551.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Res Commun

2. KO JH, Jung TW, Pyo MK, Lim DS, et al
   Senkyunolide A mitigates lipid deposition in hyperlipidemic hepatocytes through SIRT6-mediated suppression of oxidative stress and fetuin-A.
   Biochem Biophys Res Commun. 2025;771:152046.
   PubMed         Abstract available
   
   

   
   BMC Cancer

3. XU X, Jiang X, Jiang H, Yuan X, et al
   Prediction of prognosis of immune checkpoint inhibitors combined with anti-angiogenic agents for unresectable hepatocellular carcinoma by machine learning-based radiomics.
   BMC Cancer. 2025;25:888.
   PubMed         Abstract available
   
   
4. XU L, Xiao T, Chao T, Xiong H, et al
   From genes to therapy: a lipid Metabolism-Related genetic risk model predicts HCC outcomes and enhances immunotherapy.
   BMC Cancer. 2025;25:895.
   PubMed         Abstract available
   
   
5. LIANG T, He Y, Mo S, Liao Y, et al
   Predictive value of intra-hepatectomy ICGR15 of the remnant liver for post-hepatectomy liver failure in hemi-hepatectomy: a prospective study.
   BMC Cancer. 2025;25:881.
   PubMed         Abstract available
   
   
6. LU H, Gao Y, Xia X, Fu Q, et al
   RALOX-HAIC (raltitrexed + oxaliplatin) combined with lenvatinib improves survival and safety in elderly patients with unresectable hepatocellular carcinoma.
   BMC Cancer. 2025;25:882.
   PubMed         Abstract available
   
   

   
   BMC Gastroenterol

7. SALMANIZADEH F, Sabzevari S, Shafieipour S, Zahedi MJ, et al
   Challenges and needs in the management of non-alcoholic fatty liver disease from the perspective of gastroenterology and hepatology specialists: a qualitative study.
   BMC Gastroenterol. 2025;25:396.
   PubMed         Abstract available
   
   
8. ZHENG X, Wei W
   Ascites complications risk factors of decompensated cirrhosis patients: logistic regression and prediction model.
   BMC Gastroenterol. 2025;25:397.
   PubMed         Abstract available
   
   
9. SUN J, Mao S, Lu C
   Association between circadian syndrome and MASLD risk: evidence from a large cross-sectional study.
   BMC Gastroenterol. 2025;25:391.
   PubMed         Abstract available
   
   
10. WU Z, Zhang M, Tian R, Liu J, et al
    Clinical efficacy of TACE using coil or gelatin sponge combined with targeted therapy in the treatment of giant hepatocellular carcinoma with arterioportal fistulas.
    BMC Gastroenterol. 2025;25:387.
    PubMed         Abstract available
    
    
11. OKADA M, Hanayama M, Yamamoto Y, Miyake T, et al
    Effect of pemafibrate in reducing intestinal long-chain fatty acid absorption and hepatic fibrosis in metabolic dysfunction-associated steatohepatitis rats.
    BMC Gastroenterol. 2025;25:385.
    PubMed         Abstract available
    
    

    
    Br J Surg

12. LOPEZ-LOPEZ V, Mohamed AH, Lopez-Conesa A, Fernandez D, et al
    Implementing laparoscopic liver surgery in Sub-Saharan Africa: a capacity-building and hepatopancreatobiliary mentorship model.
    Br J Surg. 2025;112:znaf107.
    PubMed        
    
    

    
    Dig Dis Sci

13. JALIL S, Mumtaz K
    Heart of the Matter: Uncovering the Link Between Heart Failure and Cirrhosis Mortality.
    Dig Dis Sci. 2025 May 19. doi: 10.1007/s10620-025-09092.
    PubMed        
    
    
14. DE CARVALHO MS, Ferreira CN
    Hot TIPS-Success of Transjugular Intrahepatic Portosystemic Shunt in Patients with Cavernous Transformation of the Portal Vein.
    Dig Dis Sci. 2025 May 20. doi: 10.1007/s10620-025-09087.
    PubMed        
    
    

    
    Endoscopy

15. OGURA T, Matsuno J, Kanadani T, Aboelezz AF, et al
    Endoscopic ultrasound-guided hepaticogastrostomy using a 22G needle with a 0.018-inch ultra-stiff guidewire without tract dilation.
    Endoscopy. 2025;57.
    PubMed        
    
    
16. OGURA T, Matsuno J, Kanadani T, Aboelezz AF, et al
    Needle-free technique to prevent guidewire damage during endoscopic ultrasound-guided hepaticogastrostomy.
    Endoscopy. 2025;57.
    PubMed        
    
    
17. MIWA H, Ishino Y, Endo K, Oishi R, et al
    Endoscopic ultrasonography-guided hepaticoduodenostomy using a novel self-expandable metallic stent with an ultra-tapered tip and a slim-delivery system.
    Endoscopy. 2025;57.
    PubMed        
    
    

    
    Eur Radiol

18. WEI H, Jiang H, Yoo J, Kim JH, et al
    Temporal evolution of the LI-RADS radiation treatment response assessment on multiphase CT/MRI in patients undergoing selective internal radiation therapy for hepatocellular carcinoma.
    Eur Radiol. 2025 May 17. doi: 10.1007/s00330-025-11659.
    PubMed         Abstract available
    
    

    
    Gastroenterology

19. JUANOLA A, Ma AT, Cullaro G, Alexander MP, et al
    DEVELOPMENT OF ACUTE KIDNEY INJURY IN A PATIENT WITH ALCOHOL-RELATED CIRRHOSIS: THE IMPORTANCE OF DIAGNOSING THE CAUSE OF AKI.
    Gastroenterology. 2025 May 19:S0016-5085(25)00764.
    PubMed        
    
    
20. XUE H, Wang L, Sun D, Wu Y, et al
    Associations of alcohol consumption and genetic predisposition to hepatic steatosis with liver-related events: results from large population-based cohort studies.
    Gastroenterology. 2025 May 14:S0016-5085(25)00712.
    PubMed         Abstract available
    
    

    
    Hepatology

21. LAU G, Sangro B, Cheng AL, Kudo M, et al
    Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trial.
    Hepatology. 2025 May 16. doi: 10.1097/HEP.0000000000001385.
    PubMed         Abstract available
    
    
22. EISWERTH M, Arab JP
    A new voice in diagnosing and predicting hepatic encephalopathy.
    Hepatology. 2025;81:1623-1624.
    PubMed        
    
    
23. HARRIS K
    LPCN 1148: Rebuilding muscle memory in cirrhosis patients.
    Hepatology. 2025;81:1625-1626.
    PubMed        
    
    
24. JIANG JX, Fish SR, Tomilov A, Li Y, et al
    Erratum: Nonphagocytic activation of NOX2 is implicated in progressive nonalcoholic steatohepatitis during aging.
    Hepatology. 2025;81:E180.
    PubMed        
    
    
25. MACHIDA K, Tsukamoto H, Liu JC, Han YP, et al
    Retraction: C-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair.
    Hepatology. 2025;81:E181.
    PubMed        
    
    
26. REGHUPATY SC, Raha S, Mendoza R, Manna D, et al
    TATA-box binding protein associated factor 2 (TAF2) in hepatocyte survival and tumorigenesis.
    Hepatology. 2025 May 19. doi: 10.1097/HEP.0000000000001406.
    PubMed         Abstract available
    
    
27. XIE L, Chen H, Zhang L, Yang YY, et al
    Suppressing MASH fibrotic progression by blocking succinate-GPR91 signaling in hepatic stellate cells.
    Hepatology. 2025 May 19. doi: 10.1097/HEP.0000000000001405.
    PubMed         Abstract available
    
    
28. NGUYEN T, Shin Y, Ruppa A, Krall AS, et al
    Galectin-1 modulates glycolysis via a GM1-galactose-dependent pathway to promote hyperthermia resistance in hepatocellular carcinoma.
    Hepatology. 2025 May 21. doi: 10.1097/HEP.0000000000001391.
    PubMed         Abstract available
    
    
29. BAKRANIA A, Mo Y, Zheng G, Bhat M, et al
    RNA nanomedicine in liver diseases.
    Hepatology. 2025;81:1847-1877.
    PubMed         Abstract available
    
    
30. FAN L, Tian C, Yang W, Liu X, et al
    HKDC1 promotes liver cancer stemness under hypoxia through stabilizing beta-catenin.
    Hepatology. 2025;81:1685-1699.
    PubMed         Abstract available
    
    
31. MARINO Z, Garcia-Sola C, Rios J, Bono A, et al
    Exchangeable copper for patients with Wilson disease at follow-up: Rethinking normal ranges or changing methodology.
    Hepatology. 2025;81:1728-1739.
    PubMed         Abstract available
    
    
32. TINCOPA MA, Diaz LA, Huang DQ, Arab JP, et al
    Disparities in screening and risk stratification for Hispanic adults with metabolic dysfunction-associated steatotic liver disease.
    Hepatology. 2025;81:1792-1804.
    PubMed         Abstract available
    
    
33. CIRIA R, Ivanics T, Aliseda D, Claasen M, et al
    Liver transplantation for primary and secondary liver tumours. patient-level meta-analyses compared to unos conventional indications.
    Hepatology. 2024 Oct 28. doi: 10.1097/HEP.0000000000001129.
    PubMed         Abstract available
    
    

    
    J Gastroenterol

34. LIU WM, Chen CY, Ma HQ, Zhang QQ, et al
    Inhibition of liver cancer cell growth by metabolites S-adenosylmethionine and nicotinic acid originating from liver progenitor cells.
    J Gastroenterol. 2025;60:754-769.
    PubMed         Abstract available
    
    

    
    J Gastroenterol Hepatol

35. MATSUBARA Y, Tsuboi A, Shigenobu S, Hirata I, et al
    Clinical Significance of Small-Bowel Mucosal Changes in Liver Cirrhosis Patients With Suspected Small-Bowel Bleeding: A Capsule Endoscopy Study.
    J Gastroenterol Hepatol. 2025 May 19. doi: 10.1111/jgh.17002.
    PubMed         Abstract available
    
    
36. JOSHI A, Raja HAA, Roy P, Latif F, et al
    Comparison of Carvedilol to Propranolol in Reduction of Hepatic Venous Pressure Gradient in Liver Cirrhosis: A Meta-Analysis.
    J Gastroenterol Hepatol. 2025 May 19. doi: 10.1111/jgh.16999.
    PubMed         Abstract available
    
    

    
    J Hepatol

37. WANG Y, Wang J, Zhou Z, Gu Y, et al
    A read-through circular RNA RCRIN inhibits metabolic dysfunction-associated steatotic liver disease.
    J Hepatol. 2025;82:1068-1079.
    PubMed         Abstract available
    
    
38. INDIA-ALDANA S, Midya V, Betanzos-Robledo L, Yao M, et al
    Impact of metabolism-disrupting chemicals and folic acid supplementation on liver injury and steatosis in mother-child pairs.
    J Hepatol. 2025;82:956-966.
    PubMed         Abstract available
    
    
39. XIANG L, Wang G, Zhuang Y, Luo L, et al
    Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled study.
    J Hepatol. 2025;82:967-978.
    PubMed         Abstract available
    
    
40. CINNAMON E, Stein I, Zino E, Rabinovich S, et al
    RORc-expressing immune cells negatively regulate tertiary lymphoid structure formation and support their pro-tumorigenic functions.
    J Hepatol. 2025;82:1050-1067.
    PubMed         Abstract available
    
    

    
    Oncogene

41. SOUDAH N, Baskin A, Darash-Yahana M, Darlyuk-Saadon I, et al
    Erk1(R84H) is an oncoprotein that causes hepatocellular carcinoma in mice and imposes a rigorous negative feedback loop.
    Oncogene. 2025 May 20. doi: 10.1038/s41388-025-03437.
    PubMed         Abstract available
    
    

    
    PLoS One

42. SATTARI M, Shahaboddin ME, Akhavan Taheri M, Khalili E, et al
    Therapeutic potential of fisetin in hepatic steatosis: Insights into autophagy pathway regulation and endoplasmic reticulum stress alleviation in high-fat diet-fed mice.
    PLoS One. 2025;20:e0322335.
    PubMed         Abstract available
    
    
43. HUANG M, Li D, Xia Z, Liao S, et al
    Silencing NRF2 enhances arsenic trioxide-induced ferroptosis in hepatocellular carcinoma cells.
    PLoS One. 2025;20:e0322746.
    PubMed         Abstract available
    
    
44. CAO B, Zhou J, Xia B, Li X, et al
    Therapeutic potential of a choline-zinc-vitamin E nutraceutical complex in ameliorating thioacetamide-induced nonalcoholic fatty liver pathology in zebrafish.
    PLoS One. 2025;20:e0324164.
    PubMed         Abstract available
    
    
45. PARK S, Rim CH, Jung YK, Yim HJ, et al
    Predictability of clinical outcomes after external beam radiotherapy for hepatocellular carcinoma according to tumor marker dynamics.
    PLoS One. 2025;20:e0323450.
    PubMed         Abstract available
    
    
46. HU Y, Zhang X, Xiao Y, Wu Z, et al
    Efficacy and safety of rifaximin in preventing hepatic encephalopathy: A systematic review and meta-analysis.
    PLoS One. 2025;20:e0323359.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

47. ZHANG Y, Zuo A, Ba Y, Liu S, et al
    Cancer-associated fibroblast-derived SEMA3C facilitates colorectal cancer liver metastasis via NRP2-mediated MAPK activation.
    Proc Natl Acad Sci U S A. 2025;122:e2423077122.
    PubMed         Abstract available
    
    

    
    Semin Liver Dis

48. HUANG HYR, Schneider KM, Schneider C
    Big Data Analytics in Large Cohorts: Opportunities and Challenges for Research in Hepatology.
    Semin Liver Dis. 2025 May 21. doi: 10.1055/a-2599-3728.
    PubMed         Abstract available
    
    

    
    Transplantation

49. SAKOWITZ S, Bakhtiyar SS, Mallick S, Kaldas F, et al
    Association of Community Socioeconomic Distress With Waitlist and Survival Outcomes in Liver Transplantation.
    Transplantation. 2025 Jan 9. doi: 10.1097/TP.0000000000005328.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.